BioSpace News Archive

Drug Development

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for EDIT-301 for the treatment of transfusion-dependent beta thalassemia (TDT), enabling the Company to initiate a Phase 1/2 clinical study of EDIT-301 in TDT patients.

December 20, 2021
·
5 min read
Pharm Country

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to KORSUVA™ (difelikefalin) injection in the anti-pruritic functional category.

December 20, 2021
·
7 min read
Drug Development

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

MediWound Ltd. (Nasdaq: MDWD) (the “Company”), today announced positive initial data from seven of the maximum fifteen patients in its ongoing open-label, phase 2 pharmacology study of EscharEx®, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds.

December 20, 2021
·
8 min read
Pharm Country

CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

CytoSorbents Corporation announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.

December 20, 2021
·
8 min read
Business

Tilray to Announce Second Quarter Fiscal 2022 Financial Results on January 10, 2022Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022

Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022.

December 20, 2021
·
2 min read
InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma

InMed Pharmaceuticals Inc. today announced that a peer-reviewed scientific article entitled “ Cannabinol Modulates Neuroprotection and Intraocular Pressure has been published.

December 20, 2021
·
6 min read
Business

Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)

Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.

December 20, 2021
·
7 min read
BioMidwest

Clarametyx Biosciences Awarded $3.15 Million Grant From NIH to Advance a Broad-Spectrum Vaccine Technology for Bacterial Infections

Clarametyx Biosciences Inc. today announced the receipt of a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD) at the National Institutes of Health (NIH) for up to $3.15 million over three years.

December 20, 2021
·
3 min read
Biotech Beach

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

CG Oncology, Inc. announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan South Korea, Taiwan and other Asian countries with the exception of China.

December 20, 2021
·
2 min read
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration

ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope ® TATX-03 Antibody Cocktail Manufacturing Collaboration.

December 20, 2021
·
6 min read